| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 17.503 | 48.529 | 22.722 | 5.587 | - | 61.621 | - | - | - | - |
| Total Income - EUR | 17.503 | 48.529 | 22.722 | 5.587 | - | 61.621 | - | - | - | - |
| Total Expenses - EUR | 10.630 | 31.703 | 13.496 | 4.823 | - | 57.408 | - | - | - | - |
| Gross Profit/Loss - EUR | 6.873 | 16.826 | 9.225 | 764 | - | 4.213 | - | - | - | - |
| Net Profit/Loss - EUR | 6.348 | 15.856 | 7.528 | 375 | - | 2.476 | - | - | - | - |
| Employees | 0 | 1 | 1 | 0 | - | 0 | - | - | - | - |
Check the financial reports for the company - Profmed Therapeutics Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 1.628 | 17.337 | 40.450 | - | 38.915 | - | - | - | - |
| Current Assets | 8.558 | 26.007 | 26.260 | 14.004 | - | 42.781 | - | - | - | - |
| Inventories | 5.908 | 6.477 | 6.876 | 6.552 | - | 34.307 | - | - | - | - |
| Receivables | 2.768 | 4.522 | 17.693 | 4.516 | - | 8.245 | - | - | - | - |
| Cash | -118 | 15.008 | 1.691 | 2.937 | - | 229 | - | - | - | - |
| Shareholders Funds | 7.520 | 23.299 | 21.676 | 21.697 | - | 29.333 | - | - | - | - |
| Social Capital | 45 | 45 | 44 | 86 | - | 83 | - | - | - | - |
| Debts | 1.038 | 4.337 | 21.920 | 32.758 | - | 52.363 | - | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Profmed Therapeutics Srl